Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study.
BACKGROUND
Alterations in serum lipids and an increased risk of myocardial infarction have been associated with HIV-1 infection and its treatment.


METHODS
Lipoprotein subclasses were measured by nuclear magnetic resonance spectroscopy in frozen plasma samples from participants in the Multicenter AIDS Cohort Study. The effects of HIV-1 infection, antiretroviral therapy, and other factors on median particle concentrations were examined using quantile regression.


RESULTS
Fasted samples were tested from 1082 men, including 609 HIV-seronegative and 473 HIV-1-infected men. Compared with HIV-seronegative men, HIV-1-infected men on antiretroviral therapy had an atherogenic phenotype with higher numbers of very low density lipoprotein and small low-density lipoprotein particles and lower numbers of high-density lipoprotein and large low-density lipoprotein particles. HIV-infected, antiretroviral-naive men had significantly lower high-density lipoprotein and small low-density lipoprotein particle concentrations compared with the HIV-seronegative men. Among men on antiretroviral therapy, the atherogenic phenotype was most pronounced in men with a good clinical status.


CONCLUSIONS
Use of antiretroviral therapy in HIV-1-infected men was associated with an "atherogenic lipoprotein phenotype."
Riddler
Sharon A
SA
Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA. riddler@dom.pitt.edu
Li
Xiuhong
X
Otvos
James
J
Post
Wendy
W
Palella
Frank
F
Kingsley
Lawrence
L
Visscher
Barbara
B
Jacobson
Lisa P
LP
Sharrett
A R
AR
D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D015658:HIV Infections / Q000097:blood* / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D015497:HIV-1; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008077:Lipoproteins, LDL / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D019438:Ritonavir / Q000494:pharmacology
D017320:HIV Protease Inhibitors; D008074:Lipoproteins; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D019438:Ritonavir